Lv51
920 积分 2024-03-01 加入
Abstract CT063: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies (NCT04886622)
5小时前
求助中
Quantitative determination of betamethasone sodium phosphate and betamethasone dipropionate in human plasma by UPLC-MS/MS and a bioequivalence study
1个月前
已完结
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
3个月前
已完结
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
3个月前
已关闭
Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis
4个月前
已完结
Pharmacokinetics /pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model
5个月前
已完结
Validation of high-performance liquid chromatography–tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices
7个月前
已完结
A high-performance liquid chromatography–tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma
7个月前
已完结
皖公网安备34019202002308
